68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors — Stella

Home/Neuroendocrine Tumors/

View on ClinicalTrials.gov

Recruiting

Back to Neuroendocrine Tumors trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Canada

University of Alberta, Edmonton, Alberta

Key details

Phase

Safety & dosing

Sponsor

University of Alberta

Enrollment target

~600 participants

Started

February 2022

Primary completion

August 2027

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.